GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Clinical trials for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE trials appear
Sign up with your email to follow new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Brain cancer vaccine trial aims to stop tumor return
⭐️ VACCINE ⭐️ ENROLLING_BY_INVITATIONThis early-stage study tests two mRNA vaccines (GV-108 and GV-907) in 9 adults with a specific type of aggressive brain cancer (IDH-wildtype glioblastoma). The goal is to see if the vaccines are safe and can trigger the immune system to fight the cancer, potentially preventing re…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: EARLY_PHASE1 • Sponsor: Beijing Neurosurgical Institute • Aim: ⭐️ VACCINE ⭐️
Last updated May 08, 2026 12:04 UTC
-
Could vitamin B3 boost brain cancer treatment?
Disease control TerminatedThis study looks at adding high-dose niacin (vitamin B3) to the usual treatment for a type of aggressive brain cancer called glioblastoma. The goal is to find a safe dose and see if it helps people live longer without their cancer growing. About 59 adults with newly diagnosed gli…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated May 15, 2026 11:54 UTC